Abstract
Hepatitis C virus (HCV) infection is a global health challenge. By the end of 2021, WHO estimated that less than quarter of global HCV infections were diagnosed. There is a need for a public health tool that can facilitate identification of infected persons and linking them to testing and treatment. We derived and validated a risk score to identify infected persons in Egypt and provided a demonstration of its utility. The 2008 and 2014 Egypt Demographic and Health Surveys were used to derive two risk scores using multivariable logistic regression. Both scores showed similar dependence on sex, age, and type of place of residence. Both risk scores demonstrated high and similar areas under the curve of 0.77 (95% CI: 0.76-0.78) and 0.78 (95% CI: 0.77-0.80), respectively. For the 2008 Risk Score, sensitivity was 73.7%, specificity was 68.5%, positive predictive value (PPV) was 27.8%, and negative predictive value (NPV) was 94.1%. For the 2014 Risk Score, sensitivity was 64.0%, specificity was 78.2%, PPV was 22.2%, and NPV was 95.7%. Each score was validated by applying it to a different survey database than the one used to derive it. Implementation of HCV risk scores is an effective strategy to identify carriers of HCV infection and to link them to testing and treatment at low cost to national programs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Priorities Research Program (NPRP) [grant number 12S-0216-190094] from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors. The authors are also grateful for infrastructure support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine-Qatar.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at the Egypt Demographic and Health Survey (EDHS). All data analyzed in this study can be accessed through application to the DHS Program at https://dhsprogram.com/ or by contacting archive@dhsprogram.com.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: The Qatar National Research Fund (NPRP 12S-0216-190094).
Disclose funding received for this work: Others.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.